Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.
- Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.
- No statistically significant differences were observed between the BID and TID treatment arms and TP-03 was well tolerated.
- “We are encouraged by these early results, which underscore the potential of TP-03 to address the underlying cause of disease,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
- “We look forward to further analyzing the data from this trial and continued discussions with the U.S. Food and Drug Administration about the best path forward for TP-03 in MGD.”